Inhalon Biopharma is a Durham, North Carolina-based clinical-stage biotechnology company developing revolutionary inhaled antibody treatments for acute respiratory infections.

We are rapidly advancing programs for the treatment of multiple respiratory infections, including Respiratory Syncytial Virus (RSV), influenza, human metapneumovirus, and SARS-CoV-2. Because preventative vaccine therapies for acute respiratory infections fail to fully protect people from infection, Inhalon’s breakthrough technology has the potential to address a massive unmet need by treating active infection, directly in the lung.

Our core technology, ‘muco-trapping,’ utilizes engineered antibodies to capture pathogens within the lung mucus, effectively blocking their spread and facilitating their rapid elimination. This innovative approach represents a significant advancement in respiratory care, offering a simplified ‘test-to-treat’ model for patients.

IN-002 | Inhalon Biopharma

Product description

Inhalon Biopharma Durham, United States (US)

Price: N/A

Inhalon Biopharma
Durham, United States (US)